Cortexyme (NASDAQ:CRTX) Stock Price Up 1.4%

Share on StockTwits

Shares of Cortexyme, Inc. (NASDAQ:CRTX) rose 1.4% on Tuesday . The stock traded as high as $34.00 and last traded at $32.35, approximately 1,414 shares were traded during trading. A decline of 99% from the average daily volume of 155,184 shares. The stock had previously closed at $31.91.

Separately, Zacks Investment Research downgraded Cortexyme from a “buy” rating to a “hold” rating in a research report on Monday, October 14th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $34.00.

The firm has a 50-day moving average of $24.56 and a two-hundred day moving average of $28.42.

Cortexyme (NASDAQ:CRTX) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, hitting the consensus estimate of ($0.37). Equities analysts forecast that Cortexyme, Inc. will post -1.51 EPS for the current year.

Several hedge funds have recently made changes to their positions in CRTX. Wells Fargo & Company MN bought a new position in Cortexyme in the second quarter valued at about $191,000. JPMorgan Chase & Co. bought a new position in Cortexyme in the second quarter valued at about $78,000. Landscape Capital Management L.L.C. bought a new position in Cortexyme in the second quarter valued at about $535,000. Charles Schwab Investment Management Inc. bought a new position in Cortexyme in the second quarter valued at about $1,052,000. Finally, Bank of New York Mellon Corp bought a new position in Cortexyme in the second quarter valued at about $349,000. Institutional investors and hedge funds own 20.62% of the company’s stock.

Cortexyme Company Profile (NASDAQ:CRTX)

Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease.

See Also: Dead Cat Bounce

Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Squar Milner Financial Services LLC Purchases 96 Shares of Parker-Hannifin Corp
Squar Milner Financial Services LLC Purchases 96 Shares of Parker-Hannifin Corp
Squar Milner Financial Services LLC Purchases 347 Shares of Unilever NV
Squar Milner Financial Services LLC Purchases 347 Shares of Unilever NV
Squar Milner Financial Services LLC Acquires 50 Shares of Martin Marietta Materials, Inc.
Squar Milner Financial Services LLC Acquires 50 Shares of Martin Marietta Materials, Inc.
Squar Milner Financial Services LLC Has $100,000 Holdings in Charles River Laboratories Intl. Inc
Squar Milner Financial Services LLC Has $100,000 Holdings in Charles River Laboratories Intl. Inc
Squar Milner Financial Services LLC Has $103,000 Stock Position in Oshkosh Corp
Squar Milner Financial Services LLC Has $103,000 Stock Position in Oshkosh Corp
Squar Milner Financial Services LLC Trims Stake in Magna International Inc.
Squar Milner Financial Services LLC Trims Stake in Magna International Inc.


© 2006-2020 Ticker Report